George Fritsma

MS, MLS, Lab Scientist, Educator, Author

George Fritsma is a medical laboratory scientist, educator, and author. George contributed five chapters to Keohane EM, Butina MM, Mirza KM, Walenga JM: Rodak’s Hematology; Clinical Principles and Applications, Seventh Edition, 2025, Elsevier; and is the co-author of Bennett A, Fritsma GA, Ernst DJ: Quick Guide to Blood Collection Edition 2, 2016, Marques MB, Fritsma GA: Quick Guide to Coagulation Testing Edition 3, 2015, and Reddy V, Marques MB, Fritsma GA: Quick Guide to Hematology Testing Edition 2, 2013, along with three additional titles, all published by AACC Press. He is a consultant in the Laboratory Medicine Department of Pathology at the University of Alabama at Birmingham. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

read more

August 2025 QQ: Coagulation Control Proteins

Our August 2026 Quick Question is a simple quiz that asks, “Which is NOT an endogenous coag control protein?” This is your opportunity to review the plasma-based coagulation mechanism and recall the functions of the control proteins, available in our Educational Module entitled Coagulation Overview. One of these is NOT an endogenous control protein for […]

Comments (0)

Quick Question Archive

DOAC Pharmacodynamics and Potential Near-patient Decision Making

Access your ISTH membership or medical library for a ground-breaking JTH Forum article: Shaw JR, Ansell J. A light in the dark-reframing direct oral anticoagulant pharmacokinetics and pharmacodynamics for near-patient decision-making. J Thromb Haemost. 2026;24(8):2726-2731. doi: 10.1016/j.jtha.2026.05.016. Epub 2026 May 21. PMID: 42173287. Abstract Direct oral anticoagulant (DOAC) level testing is needed most when decisions […]

Comments (0)

Anticoagulant Therapy

Pre-barcoded Tubes Reduce Misidentification Rates

Here is an open-access survey report: Jovičić S, Verdonck A, Lippi G, Ruven H, Šimundić AM. How do pre-barcoded tubes improve preanalytical workflow? A survey study. Clin Chem Lab Med. 2026 Aug 21. doi: 10.1515/cclm-2026-0836. PMID: 42617137. Abstract Objectives Preanalytical errors account for approximately 60–70 % of all laboratory errors, with sample misidentification among the most […]

Comments (0)

Specimen Management

Hemophilia A Patient Satisfaction With Extended Half-life Altuviiio® Therapy

Click here for an open-access post hoc study report on patient satisfaction with once-weekly Altuviiio® (Efanesoctocog alfa) therapy: Spasov E, Quon D, Fukutake K, et al. Treatment satisfaction and patient preference for efanesoctocog alfa over previous hemophilia A treatment: Results from the XTEND-1 phase 3 clinical trial. Curr Ther Res Clin Exp. 2026;105:100839. doi: 10.1016/j.curtheres.2026.100839. […]

Comments (0)

Bleeding Disorders

Simplified DOAC--Stop Proof of Concept

Click here for this 2024 open-access article describing the use of DOAC-Stop®: Exner T, Dangol M, Favaloro EJ. Simplified method for removing direct oral anticoagulant interference in mechanical coagulation test systems–a proof of concept. J Clin Med. 2024;13:1042. doi: 10.3390/jcm13041042. PMID: 38398355; PMCID: PMC10889288. Abstract Background: Direct oral anticoagulants (DOACs) cause unwanted interference in various […]

Comments (0)

Anticoagulant Therapy

Type 2M VWD

A LinkedIn note by Shadi Tabibian, 2nd. Laboratory Hematologist and Director, Iranian Comprehensive Hemophilia Care Center; Deputy of Research, Blood Diseases Research Center, Iran University of Medical Sciences: Can a “normal” VWF activity-to-antigen ratio rule out Type 2 von Willebrand disease? Not always. One of the most interesting diagnostic lessons from this recent review is the […]

Comments (0)

Bleeding Disorders

A Coag Conversation: 100 Years of VWD and Upcoming Advances: Conversation 3

On August 11, 2026, we posted the third and concluding conversation of “100 Years of Von Willebrand Disease and Upcoming Advances” with Robert F. Sidonio, Jr., MD, MSc. Click here for #3: Advanced Assays and von Willebrand Disease Management.

Comments (0)

Bleeding Disorders

Effect of PCC on Bleeding Patients with FXa Inhibitor

Click here for a current study report on PCC therapy in patients with FXa inhibitors who are bleeding or needing surgery: Shaw JR, Gray H, Xu Y, et al. Effect of PCC on thrombin generation in patients on FXaI with bleeding or needing urgent surgery (GAUGE). Blood Adv. 2026;10(15):5378–88. doi: 10.1182/bloodadvances.2026020203. PMID: 42275536; PMCID: PMC13452292. […]

Comments (0)

Bleeding Disorders

ISTH Paris Summary

Thanks to Dr. Ali Sadeghi-Khomami, PBI Research Scientist, for this downloadable comprehensive summary of the ISTH meeting in Paris.

Comments (0)

Events

Events and Conferences: Bleeding Disorders Conference August 13–15

Thanks to Elaine Benoit, PBI’s marketing guru, for recent updates to our Events and Conferences Calendar. This week is the NBDF’s Bleeding Disorders Conference in Orlando, FL, USA, August 13–15. It’s not too late to register. Our colleagues at George King Bio-Medical will exhibit at booth 100. If you don’t see your hemostasis-related event or […]

Comments (0)

Events

Questions or Comments?

Email George